Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Risk-benefit of new biologicals in the treatment of chronic plaque psoriasis — AA Saad (2006) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Risk-benefit of new biologicals in the treatment of chronic plaque psoriasis
Shared by
Christopher Em Griffiths
Risk-benefit of new biologicals in the treatment of chronic plaque psoriasis
Article
2006
en
Authors
+1 more
AS
AA Saad
DA
Darren M. Ashcroft
Christopher Em Griffiths
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2013
Alemtuzumab and chronic plaque psoriasis
Aamir Aslam
,
Alexander Marsland
,
David Rog
,
Christopher Em Griffiths
Article
1985
Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment.
Barbara S. Baker
,
A.F. SWAIN
,
Christopher Em Griffiths
,
J.N. LEONARD
,
L. Fry
,
Helgi Valdimarsson
Article
2016
Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Paul Devakar Yesudian
,
Joyce Leman
,
Periasamy Balasubramaniam
,
Andy W Macfarlane
,
Firas Al‐Niaimi
,
Christopher Em Griffiths
,
Arthur David Burden
,
Richard B. Warren
Article
2000
Combination Regimens of Topical Calcipotriene in Chronic Plaque Psoriasis
Darren M. Ashcroft
,
A. Li Wan Po
,
Hywel C Williams
,
Christopher Em Griffiths
Article
2015
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib
Zenas Z N Yiu
,
Faisal R. Ali
,
Christopher Em Griffiths
.webp)
Discussion(0)
No comments yet. Be the first to comment.